EXHIBIT 10.29 UNITED STATES OF AMERICA SALES, DISTRIBUTION, AND DEVELOPMENT AGREEMENT This Sales, Distribution, and Development Agreement (the "Agreement") is made as of April 4, 2000 (the "Effective Date") by and between AVI BioPharma, Inc., ("AVI"),...Sales, Distribution, and Development Agreement • March 27th, 2001 • Avi Biopharma Inc • Pharmaceutical preparations • Delaware
ContractSales, Distribution, and Development Agreement • May 5th, 2020 • Illinois
<DOCUMENT> <TYPE>EX-99.3 <SEQUENCE>3 <FILENAME>ex-99_3.txt <DESCRIPTION>EXHIBIT 99.3 <TEXT> <PAGE> Exhibit 99.3 CONFIDENTIAL TREATMENT REQUESTED * Portions denoted with an asterisk have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. WORLDWIDE SALES, DISTRIBUTION, AND DEVELOPMENT AGREEMENT This Sales, Distribution, and Development Agreement (the "Agreement") is made as of December 21, 1999 by and between SuperGen, Inc., ("SuperGen"), a California corporation with its principal offices at Two Annabel Lane, Suite 220, San Ramon, California 94583, and Abbott Laboratories, an Illinois corporation ("Abbott"), with its principal offices at 100 Abbott Park Road, Abbott Park, Illinois 60064. RECITALS: WHEREAS, SuperGen is developing a pharmaceutical compound known as Rubitecan (as defined below) for the treatment of pancreatic cancer and other indications; WHEREAS, SuperGen desires to collaborate with Abbott with r
